Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	12.39	27.65	19.4	114.52	185.62
Short-Term Investments	91.02	102.25	154.02	69.95	160.11
Cash & Short-Term Investments	103.41	129.89	173.42	184.47	345.73
Cash Growth	-20.39%	-25.10%	-5.99%	-46.64%	350.51%
Other Current Assets	2.56	2.93	3.42	2.74	3.49
Total Current Assets	105.96	132.83	176.84	187.21	349.22
Net Property, Plant & Equipment	31.23	32.33	36.9	32.57	31.86
Long-Term Investments	52.74	76.41	90.65	129.17	16.37
Other Long-Term Assets	1.18	1.18	1.18	1.11	1
Total Assets	191.11	242.74	305.57	350.05	398.45
Accounts Payable	0.94	0.99	1.64	1.27	1.72
Accrued Expenses	3.18	2.55	3.95	3.53	3.12
Current Portion of Leases	3.83	4.1	3.54	1.99	0.97
Total Current Liabilities	7.95	7.63	9.12	6.79	5.81
Long-Term Leases	26.19	26.38	31.09	28.34	29.06
Total Long-Term Liabilities	26.19	26.38	31.09	28.34	29.06
Total Liabilities	34.14	34.01	40.21	35.13	34.87
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	488.74	481.68	467.83	455.33	444.39
Accumulated Other Comprehensive Income	0.24	0.06	-0.26	-1.85	-0.18
Retained Earnings	-332.02	-273.02	-202.24	-138.56	-80.64
Shareholders' Equity	156.97	208.73	265.35	314.92	363.58
Total Liabilities & Equity	191.11	242.74	305.57	350.05	398.45
Total Debt	30.02	30.48	34.63	30.33	30.03
Net Cash (Debt)	73.39	99.42	138.79	154.14	315.7
Net Cash Growth	-26.18%	-28.37%	-9.96%	-51.17%	338.67%
Net Cash Per Share	0.58	0.79	1.11	1.24	3.74
Book Value	156.97	208.73	265.35	314.92	363.58
Book Value Per Share	1.24	1.66	2.12	2.53	4.30
Tangible Book Value	156.97	208.73	265.35	314.92	363.58
Tangible Book Value Per Share	1.24	1.66	2.12	2.53	4.30

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q